Roger Gomis, head of the Growth Control and Cancer Metastasis Lab at IRB Barcelona, participated in the "Càpsules de ciència” video series produced by TV3. In the video he talks about his work on the biology of the metastatic process—research that may contribute to improving patients' lives.
Link to TV3
TV3, La Vanguardia, ABC, El Punt Avui, ARA, Diario Médico, Breast Cancer News, El Mundo, among other national and international media, have published an article about the latest work IRB Barcelona researcher Roger Gomis. In this study the researcher have identified genes involved in the latent asymptomatic stage of breast cancer metastases. This work sheds light on the molecular basis underlying how the expression of certain genes facilitates the spread of metastatic lesions.
Link to TV3
Yesterday, Roger Gomis, head of the Growth Control and Cancer Metastasis Lab at IRB Barcelona, participated in a round table on TV3's "Tarda Oberta" to explain the mechanism that allows metastatic cells to leave a latent state.
Link to "Tarda Oberta"
A team of scientists headed by Roger Gomis at IRB Barcelona reveals one of the mechanisms that allows metastatic cells to leave a latent state.
The “Innovadores” supplement of El Mundo publishes a report on the "Valley of Death" in biolotechnology. This term refers to the phases that between a scientific discovery and it reaching the market.
The article includes comments by experts Delia Zabra, from the Innovation Department at IRB Barcelona, and ICREA researcher Roger Gomis, founder of the spin-off company Inbiomotion.
Virgil Simons from Radio Kanal Barcelona has interviewed ICREA researcher Roger Gomis about breast cancer. Gomis is one of the co-authors of an article recently published in Lancet Oncology in which they identified a group of patients with early breast cancer who could benefit from a preventive treatment of metastasis.
Link to Radio Kanal Barcelona
ICREA researcher Roger Gomis, head of the Growth Control and Cancer Metastasis Lab, has recently been awarded a 2016 "Knowledge Industry Grant" (Producte), by the Catalan Government’s Agency for Management of University and Research Grants, for the further development of a therapy for the treatment of breast cancer. His 18-month project, "Lipid targeting in breast cancer", aims to obtain a monoclonal antibody, based on a well-defined molecular target, that is suitable for patient treatment and to complete its pre-clinical development phase.
A study published in the Lancet Oncology by an international team led by Prof Rob E. Coleman (University of Sheffield) and Prof Roger R. Gomis (IRB Barcelona) identifies the effect of MAF amplification on the outcome of treatment with adjuvant zoledronic acid in early breast cancer.
This new knowledge may be key to the early detection of patients who would benefit from zoledronic acid and those who should be spared, and both reduce disease recurrence and deaths from breast cancer.
Inbiomotion, an IRB Barcelona spin off company and financed by venture investors Ysios Capital and Caixa Capital Risc, will soon start a confirmatory trial.
Multiple media channels, both national and international, have echoed a study published by Robert E. Coleman (University of Sheffield) in the Lancet Oncology and which involved Roger Gomis (IRB Barcelona). The work allows early detection of patients who could benefit from zoledronic acid and those who should avoid it. Such early detection would thus accelerate the administration of the first preventive treatment for metastasis.
Link to JANO
The technology supplement Innovadores of the newspaper El Mundo has echoed on the award of 220,000 euros to three biomedical innovation projects underway at IRB Barcelona. This funding has been given by the Agency for Management and University and Research Grants (AGAUR, acronym in Catalan) of the Catalan Government, with the support of ERDFs.